Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Emergent BioSolutions to post earnings of $0.49 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The company had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same period in the prior year, the company earned ($1.06) earnings per share. On average, analysts expect Emergent BioSolutions to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Emergent BioSolutions Stock Up 0.2 %

EBS opened at $8.79 on Tuesday. The company has a fifty day moving average price of $8.32 and a two-hundred day moving average price of $7.59. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16.

Analyst Ratings Changes

A number of research analysts recently weighed in on EBS shares. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of Emergent BioSolutions in a research note on Friday, August 16th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.